NCT03217786Active, not recruiting
Early Post Transplant Cardiac Allograft Vasculopathy
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
Heart transplantation is an effective life-saving treatment for patients with end-stage heart disease. After a transplant, the new heart may develop narrowing in the arteries, causing heart failure, heart attacks and abnormal heart rhythms. This condition is known as cardiac allograft vasculopathy (CAV). The disease is very common, affecting almost a third of heart transplant patients by 5 years after transplant. CAV is a serious problem that causes the new heart to fail and is one of the main causes of death after transplant. Early detection of CAV is important as treatment options are poor once the disease is established. Currently, available techniques to evaluate CAV are limited by poor ability to detect disease early. The current tests usually focus on the large heart arteries and do not examine the smaller arteries that are also affected.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 11 Jul 2017
- Start date
- 12 Feb 2018
- Primary completion date
- 31 Mar 2023
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Coronary artery disease
- NCT number
- NCT03217786
What you commit to
- Study type: Observational
- Planned participants: 80
- From 12 Feb 2018 to the primary completion date, 31 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Combined solid organ transplantation.
Other illness
- Uncontrolled heart failure or myocardial infarction ≤7 days.
Other
- Contraindications to dipyridamole.
- Contraindications to aminophylline.
- Contraindications to nitroglycerin.
- Contraindications to iodinated contrast.
- Acute allograft rejection ≤1 month.
- Estimated glomerular filtration rate ≤30 mL/min.
Who the study is looking for
- Heart transplant \<3 months.
- Age ≥18 years.
- Able and willing to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.